

## VOLUME 29 1988

### SUBJECT INDEX

- Acquisition, 143  
  response patterning  
  scopolamine  
  selection delays
- Acute administration, 169  
  ethanol tolerance  
  forebrain regions  
  monoamine/metabolite content  
  selective breeding
- Adenosine analogs, 429  
  caffeine  
  drug interaction  
  monkey
- Adenosine antagonists, 433  
  caffeine  
  therapeutic agents  
  xanthines
- Adenosine receptors, 533  
  anticonvulsant activity  
  carbamazepine  
  central nervous system  
  N<sup>6</sup>-L-phenylisopropyladenosine  
  rabbits
- Adjunctive drinking, 295  
  drug self-administration  
  monkeys, rhesus  
  scheduled-induced polydipsia
- Adrenalectomy, 451  
  endogenous opioids  
   $\beta$ -endorphin  
  stress-induced analgesia
- $\beta$ -Adrenoceptors, 717  
  lordosis  
  rats, females
- Aerosol inhalation, 93  
  cocaine smoking
- Alcohol, chronic administration, 489  
  hypogonadism  
  luteinizing hormone levels  
  prolactin levels  
  testosterone levels
- Alcohol drinking, 479  
  angiotensin II  
  renin-angiotensin system  
  satiety
- Alcohol intake, 733  
  human studies  
  methamphetamine metabolism  
  urinary excretion
- Alfentanil, 573  
  brainstem site localization  
  drug interaction  
  muscle rigidity
- Alpidem, 803  
  clinical studies  
  human studies, anxious patients
- Amiloride, 257  
  4-aminopyridine  
  lingual epithelium  
  transport pathways
- Amino acids, 73  
  convulsant action  
  hyperalgesic action  
  intrathecal glycine  
  strychnine
- 4-Aminopyridine, 257  
  amiloride  
  lingual epithelium  
  transport pathways
- Amitriptyline, chronic, 681  
  animal model of depression  
  <sup>3</sup>H-imipramine binding  
  olfactory bulbectomy  
  open field  
  swimming test
- Amnesia, 625  
  diazepam  
  electroconvulsive shock  
  passive avoidance  
  piracetam  
  scopolamine
- Amphetamine  
  apomorphine, 239  
  behavioral hypersensitivity, 239  
  cocaine, 239  
  GABAergic mechanisms, 457  
  locomotor activity, 517  
  muscimol, 457  
  picrotoxin, 457  
  rotational behavior, 457  
  subchronic administration, 239  
  ultradian activity rhythms, 517
- Analgesia  
  buprenorphine, 393  
  central nervous system, 163  
  cold swim stress, 83, 163  
  hypothermia, 83  
  jump thresholds, 83  
  norepinephrine system, 83  
  opioid peptide brain levels, 163  
  schedule-controlled behavior, 393  
  tail-flick tests, 83  
  thermoregulation, 83  
  tolerance, 393  
  yohimbine, 83
- Analgesia, milk-induced, 9  
  opioid-mediated behaviors  
  stress reduction
- Angiotensin II, 479  
  alcohol drinking  
  renin-angiotensin system  
  satiety
- Animal model  
  drug behavioral reversal, 467  
  nigro-striatal dopamine system, 59  
  prolactin, 59  
  social behavioral deficit, 467  
  yawning, 59
- Animal model of depression  
  amitriptyline, chronic, 681  
  endogenous GABA, 275  
  forced swimming test, 275  
  <sup>3</sup>H-imipramine binding, 681  
  olfactory bulbectomy, 681  
  open field, 681  
  swimming test, 681
- Anorexia, 357  
  cyclo(His-Pro)  
  food intake
- Anticholinergics, 205  
  consummatory acts  
  drug interaction  
  neuroleptics  
  operant behaviors
- Anticonvulsant activity, 533  
  adenosine receptors  
  carbamazepine  
  central nervous system  
  N<sup>6</sup>-L-phenylisopropyladenosine  
  rabbits
- Antinociception, 351  
  delta antagonists  
  ICI 154129  
  ICI 174864  
  route of administration
- Antipsychotic drug exposure, 45  
  developmentally disabled  
  dyskinesia  
  human studies
- Anxiety  
  anxiolytic drugs, 767, 771  
  barbiturates, 631  
  behavioral inhibition system, 767  
  buspirone, 821  
  conflict behavior, 631  
  convulsants, 631  
  cyclohexylideneethyl-5-barbituric acid,  
    631  
  depression, 819  
  5HT<sub>2</sub> receptors, 819  
  punishment suppression, 771
- Anxiolytic drug effects, 771  
  anxiety  
  punishment suppression
- Anxiolytic drugs, 767  
  anxiety  
  behavioral inhibition system
- Apomorphine  
  amphetamine, 239  
  behavioral differences, 529  
  behavioral hypersensitivity, 239  
  cocaine, 239  
  dose-dependent effects, 343  
  ethanol reinforcement, 343  
  haloperidol, 343, 529  
  schedule-induced polydipsia, 483  
  sex differences, 529  
  subchronic administration, 239
- Apparatus  
  radial arm maze, 143
- Appetite suppressing drugs, 675  
  brown adipose tissue  
  fenfluramine  
  sympathetic firing rate
- Arecoline, 587  
  discriminative stimuli  
  nicotine  
  non-cholinergic mechanism
- Arthritis, ankle joint, 461  
  drug interactions  
  sodium nitrate crystals
- Atropine methyl nitrate, 231  
  real-feeding/sham-feeding comparisons  
  sucrose

- Baclofen, 189
  - chronic administration
  - desipramine
  - drug interaction
  - functional response
  - 4,5,6,7-tetrahydroisoxazolo (4,5-c) pyridin-3-ol
- Barbital, 183
  - brain monoamines
  - ethanol
  - lorazepam
  - motor impairment
  - selective breeding
- Barbiturates, 631
  - anxiety
  - conflict behavior
  - convulsants
  - cyclohexylideneethyl-5-barbituric acid, 631
- Behavior, fenfluramine-induced, 565
  - fenfluramine
  - pyridoxine
  - serotonin
  - tryptophan
- Behavioral differences, 529
  - apomorphine
  - haloperidol
  - sex differences
- Behavioral effects, 411
  - caffeine
  - tolerance
- Behavioral hypersensitivity, 239
  - amphetamine
  - apomorphine
  - cocaine
  - subchronic administration
- Behavioral inhibition, 125
  - drug interaction
  - ketanserin
  - methamphetamine analog
  - para-chlorophenylalanine
- Behavioral inhibition system, 767
  - anxiety
  - anxiolytic
- Behavioral interactions, 63
  - caffeine
  - drug interaction
  - fixed interval schedule
  - nicotine
- Behavioral tests, 315
  - chlordiazepoxide actions
  - drug interaction
  - ethanol actions
  - Ro15-1788 effects
- Behavioral thermoregulation, 243
  - ethanol
  - goldfish
  - thermoregulatory set point
  - tolerance
- Behavioral toxicity, 309
  - cholinesterase inhibition
  - clonidine
  - soman
- Benzodiazepine receptor agonists, 791
  - electroencephalographic changes
  - short-term exposure
- Benzodiazepine receptor binding, 471
  - differential modulation
  - ethanol
  - strain differences
  - stress
- Benzodiazepine receptor ligands, 799
  - sleep pharmacology
- Benzodiazepine receptors
  - brain electrical activity, 785
  - imidazopyridines, 763
  - omega receptor subtypes, 763
  - rabbit/rat comparisons, 785
- Benzodiazepines, 753
  - physical dependence
  - withdrawal
- Binding, 775
  - preclinical studies
  - pyrazolopyridine non-benzodiazepine anxiolytics
- Blood ethanol levels, 509
  - cognitive-perceptual tasks
  - ethanol
  - human studies, females
  - self-rated ethanol effects
- Body weight, 667
  - circadian rhythm
  - dose-dependent effects
  - drinking
  - eating
  - ethanol
  - wheel-running activity
- Brain
  - amygdala, 613
  - anterior striatum, 169
  - basal forebrain, 581
  - basal ganglia, 595
  - brainstem, 183, 275
  - caudate-putamen, 525
  - cerebellum, 183
  - cerebral cortex, 681
  - cortex, 183, 213, 275, 613
  - dorsal hippocampus, 785
  - frontal cortex, 169, 183, 275, 595
  - hippocampus, 613
  - hypothalamus, 163, 169, 183, 275, 541, 613, 681
  - limbic forebrain, 183
  - medulla oblongata, 613
  - mesolimbic area, 595
  - neocortex, 785
  - nucleus accumbens, 169, 175, 275
  - nucleus locus coeruleus, 1
  - nucleus raphe pontis, 573
  - pons, 613
  - raphe nucleus, 97, 573
  - red nucleus, 785
  - striatum, 183, 213, 275, 457, 595
  - substantia nigra, 595
  - substantia nigra, pars reticulata, 89
  - thalamus, 613
  - ventromedial hypothalamic nucleus, 303
- Brain amine metabolism, 115
  - breakfast
  - monkeys, vervet
  - social behavior
- Brain electrical activity, 785
  - benzodiazepine receptors
  - rabbit/rat comparisons
- Brain monoamines, 183
  - barbital
  - ethanol
  - lorazepam
  - motor impairment
  - selective breeding
- Brain self-stimulation, 209
  - diprenorphine
  - fixed-ratio schedule
  - naloxone
- Brain serotonin, 559
  - dietary pyridoxine
  - histadine
  - histamine metabolism
  - tryptophan
- Brain serotonin neurons, 269
  - MDMA
  - neurotoxicity
- Brainstem site localization, 573
  - alfentanil
  - drug interaction
  - muscle rigidity
- Breakfast, 115
  - brain amine metabolism
  - monkeys, vervet
  - social behavior
- 4-Bromo-2,5-dimethoxyamphetamine, 281
  - monkeys
  - operant behavior
  - variability of effects
- Brown adipose tissue
  - appetite suppressing drugs, 675
  - chronic alcohol intake, 53
  - cold acclimation, 53
  - fenfluramine, 675
  - GDP-binding, 33
  - nicotine, 33
  - oxidative enzymes, 53
  - sympathetic firing rate, 675
  - thermogenesis, 33
- Buprenorphine, 393
  - analgesia
  - schedule-controlled behavior
  - tolerance
- Buspirone
  - anxiety, 821
  - central dopaminergic system, 823
  - complex effects, 823
  - gepirone, 711
  - 5-hydroxytryptamine<sub>1A</sub>, 711
  - imipramine, 815
  - ipsapirone, 711
  - multiple effects, 823
  - panic disorder, 815
  - placebo, 815
  - receptor-mediated effects, 711
- Caffeine
  - adenosine analogs, 429
  - adenosine antagonists, 433
  - behavioral effects, 411
  - behavioral interactions, 63
  - drug interaction, 63, 429
  - fixed interval schedule, 63
  - human studies, 419
  - monkey, 429.
  - nicotine, 63
  - reinforcing properties, 419
  - therapeutic agents, 433
  - tolerance, 411
  - xanthines, 433
- Calcium antagonist, 129
  - gastrointestinal motility
  - stress ulceration
- Calcium channels, 381
  - dyskinesia
  - iminodipropionitrile
  - nifedipine
- Cannabinoids, 213

- neurochemical development
- perinatal exposure
- tyrosine hydroxylase activity
- Captopril, 547
  - 2-deoxyglucose
  - enalapril
  - food intake
  - injectant pH
- Carbamazepine, 533
  - adenosine receptors
  - anticonvulsant activity
  - central nervous system
  - N<sup>6</sup>-L-phenylisopropyladenosine
  - rabbits
- Carbon monoxide levels, 23
  - cigarette smoking
  - EEG
  - heart rate
  - human studies
  - nicotine delivery
  - photoc driving
  - visual evoked potentials
- Catalepsy
  - D-1/D-2 receptor blockade, 223
  - drug interaction, 223
  - haloperidol, 335
  - prostaglandin levels, 335
  - radiation, 335
  - receptor effects, 223
- Caudate-putamen, 525
  - dyskinesia
  - 3-mercaptopropionic acid
  - unilateral administration
- Central dopaminergic system, 823
  - bupirone
  - complex effects
  - multiple effects
- Central nervous system
  - adenosine receptors, 533
  - analgesia, 163
  - anticonvulsant activity, 533
  - carbamazepine, 533
  - cold swim stress, 163
  - opioid peptide brain levels, 163
  - N<sup>6</sup>-L-phenylisopropyladenosine, 533
  - rabbits, 533
- Central responses, 217
  - cholinergic drugs
  - REM sleep deprivation
- CGS 8216, 741
  - dose-dependent effects
  - drug comparisons
  - monkeys
  - schedule-controlled behavior
- Chew rate, 747
  - human studies, males
  - nicotine gum
  - plasma nicotine
  - subjective effects
- Chlordiazepoxide actions, 315
  - behavioral tests
  - drug interaction
  - ethanol actions
  - R015-1788 effects
- Cholinergic drugs, 217
  - central responses
  - REM sleep deprivation
- Cholinergic muscarinic binding, 581
  - lesions, basal forebrain
  - passive avoidance retention
- Cholinergically-based learning, 325
  - Morris water task
- strain differences
- Cholinesterase inhibition, 309
  - behavioral toxicity
  - clonidine
  - soman
- Chronic administration
  - baclofen, 189
  - cocaine, 755
  - desipramine, 189
  - drug interaction, 189
  - functional response, 189
  - self-stimulation, 755
  - 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-ol, 189
  - train-duration thresholds, 755
- Chronic alcohol intake, 53
  - brown adipose tissue
  - cold acclimation
  - oxidative enzymes
- Cigarette smoking, 23
  - carbon monoxide levels
  - EEG
  - heart rate
  - human studies
  - nicotine delivery
  - photoc driving
  - visual evoked potentials
- Circadian fluctuations, 595
  - Met-enkephalin-like immunoreactivity
  - pain responsiveness
- Circadian rhythm, 667
  - body weight
  - dose-dependent effects
  - drinking
  - eating
  - ethanol
  - wheel-running activity
- Clinical pharmacology, 797
  - non-benzodiazepine anxiolytics
- Clinical studies
  - alpidem, 803
  - general practice, 811
  - human studies, anxious patients, 803
  - hypnotic agents, 811
- Clonidine
  - behavioral toxicity, 309
  - cholinesterase inhibition, 309
  - human studies, males, 649
  - marijuana, 649
  - physiologic effects, 649
  - soman, 309
  - subjective effects, 649
- Cocaine
  - amphetamine, 239
  - apomorphine, 239
  - behavioral hypersensitivity, 239
  - chronic administration, 755
  - self-stimulation, 755
  - subchronic administration, 239
  - train duration thresholds, 755
- Cocaine effects, 157
  - heart rate
  - inbred strains
  - locomotor activity
- Cocaine smoking, 93
  - aerosol inhalation
- Cognitive-perceptual tasks, 509
  - blood ethanol levels
  - ethanol
  - human studies, females
  - self-rated ethanol effects
- Cold acclimation, 53
  - brown adipose tissue
  - chronic alcohol intake
  - oxidative enzymes
- Cold water swim stress
  - analgesia, 83, 163
  - central nervous system, 163
  - hypothermia, 83
  - jump thresholds, 83
  - norepinephrine system, 83
  - opioid peptide brain levels, 163
  - tail-flick tests, 83
  - thermoregulation, 83
  - yohimbine, 83
- Complex effects, 823
  - central dopaminergic system
  - bupirone
  - multiple effects
- Conflict behavior, 631
  - anxiety
  - barbiturates
  - convulsants
  - cyclohexylideneethyl-5-barbituric acid
- Consummatory acts, 205
  - anticholinergics
  - drug interaction
  - neuroleptics
  - operant behavior
- Convulsant action, 73
  - amino acids
  - hyperalgesic action
  - intrathecal glycine
  - strychnine
- Convulsants, 631
  - anxiety
  - barbiturates
  - conflict behavior
  - cyclohexylideneethyl-5-barbituric acid
- Corticosterone, 699
  - exogenous administration
  - oxytocin
  - prolactin
  - psychological stress
- Cross-tolerance, 365
  - ethanol
  - nicotine
  - tolerance
- Cyclic Alternating Pattern Rate, 827
  - homeostasis
  - sleep organization
  - white noise
  - zolpidem
- Cyclohexylideneethyl-5-barbituric acid, 631
  - anxiety
  - barbiturates
  - conflict behavior
  - convulsants
- Cyclo(His-Pro), 357
  - anorexia
  - food intake
- Cyclopyrrolone hypnotic, 831
  - zopiclone
- D-1/D-2 receptor blockade, 223
  - catalepsy
  - drug interaction
  - receptor effects
- Decerebration, 725
  - ethylketazocine
  - hyperalgesia
  - nicotine
- Delta antagonists, 351

- antinociception
  - ICI 154129
  - ICI 174864
  - route of administration
- 2-Deoxyglucose, 547
  - captopril
  - enalapril
  - food intake
  - injectant pH
- Depression, 819
  - anxiety
  - 5HT<sub>2</sub> receptors
- Desensitization, 375
  - nicotinic receptors
  - seizures, nicotine induced
- Desipramine, 189
  - baclofen
  - chronic administration
  - drug interaction
  - functional response
  - 4,5,7,7-tetrahydroisoxazolo (5,4-c) pyridin-3-ol
- Developmentally disabled, 45
  - antipsychotic drug exposure
  - dyskinesia
  - human studies
- Diabetes, 495
  - energy balance
  - morphine
  - nalmefene
  - opioids
- Diazepam, 625
  - amnesia
  - electroconvulsive shock
  - passive avoidance
  - piracetam
  - scopolamine
- Dietary pyridoxine, 559
  - brain serotonin
  - histadine
  - histamine metabolism
  - tryptophan
- Differential modulation, 471
  - benzodiazepine receptor binding
  - ethanol
  - strain differences
  - stress
- Diprenorphine, 209
  - brain self-stimulation
  - fixed-ratio schedule
  - naloxone
- Discriminative effects, 201
  - morphine
  - reduced body weight
  - restricted feeding
- Discriminative stimuli, 587
  - arecoline
  - nicotine
  - non-cholinergic mechanism
- Dose-dependent effects
  - apomorphine, 343
  - body weight, 667
  - CGS 8216, 741
  - circadian rhythm, 667
  - drinking, 667
  - drug comparisons, 741
  - eating, 667
  - ethanol, 667
  - ethanol reinforcement, 343
  - haloperidol, 343
  - monkeys, 741
  - schedule-controlled behavior, 741
  - wheel-running activity, 667
- Dosing procedure, 553
  - human studies
  - marijuana smoke
- Dopamine receptor agonist, 89
  - intranigral injections
  - rotation
- 8-OH-DPAT, 193
  - drug discrimination
  - ipsapirone
  - stimulus properties
  - yohimbine
- Drinking
  - body weight, 667
  - circadian rhythm, 667
  - dose-dependent effects, 667
  - ethanol, 39, 667
  - d-fenfluramine, 687
  - naloxone, 39
  - saccharin preference, 687
  - wheel-running activity, 667
- Drinking modification, 331
  - naloxone
- Droperidol, 609
  - drug interaction
  - motor coordination
  - mu receptor agonists
- Drug
  - ACTH (4-10), 635
  - alanine, 303
  - alcohol, 489, 733
  - alfentanil, 573
  - alpidem, 803
  - amiflamine, 97
  - amitryptiline, 681
  - amphetamine, 239, 249, 287, 457, 517, 645
  - d-amphetamine, 403
  - apomorphine, 59, 223, 239, 249, 343, 403, 483, 529
  - arecoline, 587, 635
  - atropine, 309
  - atropine methyl nitrate, 231
  - baclofen, 189
  - barbital, 183
  - bicuculline, 275, 321
  - bromocriptine, 223, 489
  - 4-bromo-2,5-dimethoxyamphetamine, 281
  - buprenorphine, 393
  - buspirone, 711, 815, 821, 823
  - caffeine, 63, 411, 419, 429
  - cannabidiol, 213
  - capsaicin, 461
  - captopril, 547
  - carbamazepine, 533
  - CGS 8216, 741
  - chlordiazepoxide, 315
  - m-chlorophenylpiperazine, 467
  - cimoxatone, 97
  - CI 218,872, 785, 791
  - clenbuterol, 467
  - clomipramine chlorhydrate, 467
  - clonazepam, 785, 791
  - clonidine, 287, 309, 635, 649, 741
  - cocaine, 157, 239, 295, 755
  - colchicine, 461
  - "crack", 93
  - cyclohexylideneethyl-5-barbituric acid, 631
  - cyclo(His-Pro), 357
  - (-)-cytisine, 725
- DADLE, 387
- DAME, 387
- 4-deoxypyridoxine, 275
- desipramine, 189
- dexamethasone, 451, 461
- diazepam, 295, 467, 625, 741, 753, 785, 791
- diethyldithiocarbamate, 287
- diprenorphine, 209
- dopamine, 483
- 8-OH-DPAT, 193
- droperidol, 609
- enalapril, 547
- ethanol, 39, 53, 105, 133, 169, 183, 243, 315, 321, 365, 471, 509, 601, 667, 693, 725
- 5'-N-ethylcarboxamidoadenosine 429
- fenfluramine, 675
- d-fenfluramine, 687
- fenfluramine chlorhydrate, 467
- fentanyl, 609
- FK-33824, 387
- flunitrazepam, 785, 791
- fluoxetine, 635
- $\beta$ -funaltrexamine, 351
- gepirone, 711
- glycine, 303
- guanethidine, 461
- haloperidol, 205, 335, 343, 529
- hexamethonium, 451
- 8-hydroxy-2-(di-n-propylamino) tetralin, 467
- ibotenic acid, 403
- ICI 154129, 351
- ICI 174864 351
- ICI 190,622, 775
- iminodipropionitrile, 381
- imipramine, 815
- imipramine chlorhydrate, 467
- indolpine, 467
- ipsapirone, 193, 711
- isoniazide, 275
- ketanserin, 125
- lithium chloride, 79
- (-)-lobeline, 725
- lorazepam, 183
- marijuana, 649
- MDMA, 645
- mecamylamine, 725
- 3-mercaptopropionic acid, 525
- mesulergine, 197
- 5-methoxy-N-N-dimethyltryptamine, 467
- 5-methoxy-3 (1,2,3,6-tetrahydro-pyridin-4-yl) 1-H indole, 467
- methsuximide, 641
- 3,4-methylendioxyamphetamine, 269
- methylnaloxonium, 573
- alpha-benzyl-N-methylphenethylamine, 125
- (+)-methylpiperidine, 725
- methysergide, 645
- metyrapone, 451
- moclobemide, 97
- molindone, 223
- morphine, 175, 201, 387, 397, 461, 495, 609, 617
- muscimol, 321, 457
- nalmefene, 495
- naloxone, 39, 163, 209, 331, 351, 387,

- 613, 635, 705
- naltrexone, 9, 725
- nicotine, 33, 63, 365, 375, 587, 661
- (-)-nicotine, 725
- (+)-nicotine, 725
- nifedipine, 381
- nitrendipine, 129
- para-chlorophenylalanine, 97, 125
- pentazocine, 397
- pentobarbital, 471
- phenoxybenzamine, 287
- phenylbutazone, 461
- phenylethylamine, 287
- N<sup>6</sup>-L-phenylisopropyladenosine, 533
- R-N<sup>6</sup>-phenylisopropyladenosine, 429
- phenylpropanolamine, 79
- physostigmine, 59
- picrotoxin, 275, 321, 457
- pindolol, 197
- piracetam, 625
- piribedil, 635
- progesterone, 303
- propranolol, 197
- quinpirole, 89
- reserpine, 451
- Ro15-1788, 315, 741, 753
- SCH 23390, 223
- scopolamine, 15, 143, 205, 625
- serotonin, 387
- SKF 38393, 89, 223
- sodium nitrate crystals, 461
- sodium valproate, 275
- soman, 309
- streptozotocin, 495
- strychnine, 73, 303
- sufentanil, 609
- taurine, 303
- Δ<sup>9</sup>-tetrahydrocannabinol, 67, 213
- 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-ol, 189
- toloxatone, 97
- tripelennamine, 397
- 1-(3-trifluoromethylphenyl)piperazine, 197, 467
- Wy-47,037, 129
- yohimbine, 83, 193
- zopiclone, 785, 831
- zolpidem, 781, 785, 807, 827
- Drug behavioral reversal, 467
  - animal model
  - social behavioral deficit
- Drug comparisons, 741
  - CGS 8216
  - dose-dependent effects
  - monkeys
  - schedule-controlled behavior
- Drug discrimination
  - drug interactions, 397
  - ipsapirone, 193
  - 8-OH-DPAT, 193
  - morphine, 397
  - pentazocine, 397
  - pigeons, 397
  - stimulus properties, 193
  - tripelennamine, 397
  - yohimbine, 193
- Drug dose, 635
  - memory enhancement
  - training-testing interval
- Drug interaction
  - adenosine analogs, 429
  - alfentanil, 573
  - centicholinergics, 205
  - arthritis, ankle joint, 461
  - baclofen, 189
  - behavioral inhibition, 125
  - behavioral interactions, 63
  - behavioral tests, 315
  - brainstem site localization, 573
  - caffeine, 63, 429
  - cataplexy, 223
  - chronic administration, 189
  - chlordiazepoxide actions, 315
  - consummatory acts, 205
  - D-1/D-2 receptor blockade, 223
  - desipramine, 189
  - droperidol, 609
  - drug discrimination, 397
  - ethanol actions, 315
  - feeding behavior regulation, 387
  - fixed interval schedule, 63
  - food deprivation, 387
  - functional response, 189
  - ketanserin, 125
  - methamphetamine analog, 125
  - monkey, 429
  - morphine, 387, 397
  - motor coordination, 609
  - mu receptor agonists, 609
  - muscle rigidity, 573
  - naloxone, 387
  - neuroleptics, 205
  - nicotine, 63
  - operant behaviors, 205
  - opioids, 387
  - para-chlorophenylalanine, 125
  - pentazocine, 397
  - pigeons, 397
  - receptor effects, 223
  - Ro15-1788 effects, 315
  - route of administration, 387
  - sodium nitrate crystals, 461
  - 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-ol, 189
  - tripelennamine, 397
- Drug self-administration, 295
  - adjunctive drinking
  - monkeys, rhesus
  - scheduled-induced polydipsia
- Dyskinesia
  - antipsychotic drug exposure, 45
  - calcium channels, 381
  - caudate-putamen, 525
  - developmentally disabled, 45
  - human studies, 45
  - iminodipropionitrile, 381
  - 3-mercaptopropionic acid, 525
  - nifedipine, 381
  - unilateral administration, 525
- Eating
  - body weight, 667
  - circadian rhythm, 667
  - dose-dependent effects, 667
  - ethanol, 667
  - d-fenfluramine, 687
  - saccharin preference, 687
  - wheel-running activity, 667
- EEG, 23
  - carbon monoxide levels
  - cigarette smoking
  - heart rate
  - human studies
  - nicotine delivery
  - photoc driving
  - visual evoked potentials
- Electroconvulsive shock, 625
  - amnesia
  - diazepam
  - passive avoidance
  - piracetam
  - scopolamine
- Electroencephalographic changes, 791
  - benzodiazepine receptor agonists
  - short-term exposure
- Enalapril, 547
  - captopril
  - 2-deoxyglucose
  - food intake
  - injectant pH
- Energy balance, 495
  - diabetes
  - morphine
  - nalmefene
  - opioids
- Endocrine response, 1
  - lesion, neurochemical
  - neophobia
  - nucleus locus coeruleus
  - stress
- Endogenous GABA, 275
  - animal model of depression
  - forced swimming test
- Endogenous opioids, 451
  - adrenalectomy
  - β-endorphin
  - stress-induced analgesia
- β-Endorphin, 451
  - adrenalectomy
  - endogenous opioids
  - stress-induced analgesia
- Met-Enkephalin-like immunoreactivity, 595
  - circadian fluctuations
  - pain responsiveness
- Estradiol benzoate, 303
  - lordosis
  - ovariectomy
  - strychnine
  - ventromedial hypothalamic nucleus
- Ethanol
  - barbital, 183
  - behavioral thermoregulation, 243
  - benzodiazepine receptor binding, 471
  - blood ethanol levels, 509
  - body weight, 667
  - brain monoamines, 183
  - circadian rhythm, 667
  - cognitive-perceptual tasks, 509
  - cross-tolerance, 365
  - differential modulation, 471
  - dose-dependent effects, 667
  - drinking, 39, 667
  - eating, 667
  - GABAergic mechanisms, 321
  - genetic correlation, 601
  - goldfish, 243
  - human studies, females, 509
  - hyperbaric environment, 133
  - hyperthermia, 693
  - hypothermia, 693
  - lorazepam, 183
  - memory consolidation, 321
  - motor impairment, 183
  - naloxone, 39

- nicotine, 365
- passive avoidance, 321
- pressure reversal, 133
- selective breeding, 183
- self-rated ethanol effects, 509
- spontaneous behavior, 133
- strain differences, 471
- stress, 471
- thermoregulation, 693
- thermoregulatory set point, 243
- tolerance, 243, 365
- voluntary consumption, 601
- wheel-running activity, 667
- withdrawal, 601
- Ethanol actions, 315
  - behavioral tests
  - chlordiazepoxide actions
  - drug interactions
  - Ro15-1788 effects
- Ethanol reinforcement, 343
  - apomorphine
  - dose-dependent effects
  - haloperidol
- Ethanol tolerance
  - acute administration, 169
  - forebrain regions, 169
  - monoamine/metabolite content, 169
  - operant behavior, 105
  - selective breeding, 169
- Ethylketazocine, 725
  - decerebration
  - hyperalgesia
  - nicotine
- Exogenous administration, 699
  - corticosterone
  - oxytocin
  - prolactin
  - psychological stress
- Feeding behavior regulation, 387
  - drug interaction
  - food deprivation
  - morphine
  - naloxone
  - opioids
  - route of administration
- Feeding/hoarding inhibition, 79
  - malaise
  - phenylpropanolamine
- Fenfluramine
  - appetite suppressing drugs, 675
  - behavior, fenfluramine-induced, 565
  - brown adipose tissue, 675
  - pyridoxine, 565
  - serotonin, 565
  - sympathetic firing rate, 675
  - tryptophan, 565
- d-Fenfluramine, 687
  - drinking
  - eating
  - saccharin preference
- Fixed interval schedule, 63
  - behavioral interactions
  - caffeine
  - drug interaction
  - nicotine
- Fixed ratio schedule, 209
  - brain self-stimulation
  - diprenorphine
  - naloxone
- Food deprivation, 387
  - drug interaction
  - feeding behavior regulation
  - morphine
  - naloxone
  - opioids
  - route of administration
- Food intake
  - anorexia, 357
  - captopril, 547
  - cyclo(His-Pro), 357
  - 2-deoxyglucose, 547
  - enalapril, 547
  - injectant pH, 547
  - lesions, kainic acid, 175
  - lesions, nucleus accumbens, 175
  - morphine, 175
  - operant behavior, 175
  - self-administration, 175
  - water intake, 175
- Forced swimming test, 275
  - animal model of depression
  - endogenous GABA
- Forebrain regions, 169
  - acute administration
  - ethanol tolerance
  - monoamine/metabolite content
  - selective breeding
- Functional response, 189
  - baclofen
  - chronic administration
  - desipramine
  - drug interaction
  - 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-ol
- GABA<sub>A</sub> receptor supramolecular complex, 781
  - $\omega_1$  recognition sites
  - zolpidem
- GABAergic mechanisms
  - amphetamine, 457
  - ethanol, 321
  - memory consolidation, 321
  - muscimol, 457
  - passive avoidance, 321
  - picrotoxin, 457
  - rotational behavior, 457
- Gastrointestinal motility, 129
  - calcium antagonist
  - stress ulceration
- GDP-binding, 33
  - brown adipose tissue
  - nicotine
  - thermogenesis
- General practice, 811
  - clinical studies
  - hypnotic agents
- Genetic analysis, 501
  - seizures, 3-mercaptopropionic acid-induced
  - strain differences
- Genetic correlation, 601
  - ethanol
  - voluntary consumption
  - withdrawal
- Gepirone, 711
  - buspirone
  - 5-hydroxytryptamine<sub>1A</sub>
  - ipsapirone
  - receptor-mediated effects
- Goldfish, 243
  - behavioral thermoregulation
  - ethanol
  - thermoregulatory set point
  - tolerance
- Gonadectomy, 705
  - naloxone
  - opioid mediation
  - sex differences
  - swim analgesia
- Habituation, 249
  - motility
  - stereotypy
  - stimulant effects
- Haloperidol
  - apomorphine, 343, 529
  - behavioral differences, 529
  - cataplexy, 335
  - dose-dependent effects, 343
  - ethanol reinforcement, 343
  - prostaglandin levels, 335
  - radiation, 335
  - sex differences, 529
- Heart rate
  - carbon monoxide levels, 23
  - cigarette smoking, 23
  - cocaine effects, 157
  - EEG, 23
  - human studies, 23
  - inbred strains, 157
  - locomotor activity, 157
  - nicotine delivery, 23
  - photic driving, 23
  - visual evoked potential, 23
- Histadine, 559
  - brain serotonin
  - dietary pyridoxine
  - histamine metabolism
  - tryptophan
- Histamine metabolism, 559
  - brain serotonin
  - dietary pyridoxine
  - histadine
  - tryptophan
- Homeostasis, 827
  - Cyclic Alternating Pattern Rate
  - sleep organization
  - white noise
  - zolpidem
- Hormone
  - estradiol benzoate, 303
  - plasma corticosterone, 151
  - progesterone, 303
  - prolactin, 59, 151
  - thyrotropin releasing hormone, 357
- 5HT<sub>2</sub> receptors, 819
  - anxiety
  - depression
- Human studies
  - alcohol intake, 733
  - antipsychotic drug exposure, 45
  - caffeine, 419
  - carbon monoxide levels, 23
  - cigarette smoking, 23
  - developmentally disabled, 45
  - dosing procedure, 553
  - dyskinesia, 45
  - EEG, 23
  - heart rate, 23
  - marijuana smoke, 553
  - methamphetamine metabolism, 733

- nicotine delivery, 23
- photic driving, 23
- reinforcing properties, 419
- urinary excretion, 733
- visual evoked potentials, 23
- Human studies, anxious patients, 803
  - alpidem
  - clinical studies
- Human studies, females, 509
  - blood ethanol levels
  - cognitive-perceptual tasks
  - ethanol
  - self-rated ethanol effects
- Human studies, males
  - chew rate, 747
  - clonidine, 649
  - marijuana, 649
  - nicotine gum, 747
  - physiologic effects, 649
  - plasma nicotine, 747
  - subjective effects, 649, 747
- 5-Hydroxytryptamine<sub>1A</sub>, 711
  - buspirone
  - gepirone
  - ipsapirone
  - receptor-mediated effects
- Hyperactivity, 645
  - locomotor activity
  - MDMA
  - methysergide
- Hyperalgesia, 725
  - decerebration
  - ethylketazocine
  - nicotine
- Hyperalgesic action, 73
  - amino acids
  - convulsant action
  - intrathecal glycine
  - strychnine
- Hyperbaric environment, 133
  - ethanol
  - pressure reversal
  - spontaneous behavior
- Hyperthermia, 693
  - ethanol
  - hypothermia
  - thermoregulation
- Hypnotic agents, 811
  - clinical studies
  - general practice
- Hypogonadism, 489
  - alcohol, chronic administration
  - luteinizing hormone levels
  - prolactin levels
  - testosterone levels
- Hypothalamic dynorphin, 541
  - nocturnal depletion
  - rats, anorexic, tumor bearing
- Hypothermia
  - analgesia, 83
  - cold water swims, 83
  - ethanol, 693
  - hyperthermia, 693
  - jump thresholds, 83
  - norepinephrine system, 83
  - tail-flick tests, 83
  - thermoregulation, 83, 693
  - yohimbine, 83
- Ibotenic acid, 403
  - lesions, striatal
- rotational behavior
  - ICI 154129, 351
  - antinociception
  - delta antagonists
  - ICI 174864
  - route of administration
  - ICI 174864, 351
  - antinociception
  - delta antagonists
  - ICI 154129
  - route of administration
- Imidazopyridines, 763
  - benzodiazepine receptors
  - omega receptor subtypes
- Iminodipropionitrile, 381
  - calcium channels
  - dyskinesia
  - nifedipine
- Imipramine, 815
  - buspirone
  - panic disorder
  - placebo
- <sup>3</sup>H-Imipramine binding, 681
  - amitryptiline, chronic
  - animal model of depression
  - olfactory bulbectomy
  - open field
  - swimming test
- Immobilization stress, 613
  - naloxone
  - noradrenaline release
  - opiate peptide levels
- Inbred strains, 157
  - cocaine effects
  - heart rate
  - locomotor activity
- Injectant pH, 547
  - captopril
  - 2-deoxyglucose
  - enalapril
  - food intake
- Intranigral injections, 89
  - dopamine receptor agonist
  - rotation
- Intrathecal glycine, 73
  - amino acids
  - convulsant action
  - hyperalgesic action
  - strychnine
- Ipsapirone
  - buspirone, 711
  - 8-OH-DPAT, 193
  - drug discrimination, 193
  - gepirone, 711
  - 5-hydroxytryptamine<sub>1A</sub>, 711
  - receptor-mediated effects, 711
  - stimulus properties, 193
  - yohimbine, 193
- Jump thresholds, 83
  - analgesia
  - cold water swims
  - hypothermia
  - norepinephrine system
  - tail-flick tests
  - thermoregulation
  - yohimbine
- Ketanserin, 125
  - behavioral inhibition
- drug interaction
  - methamphetamine analog
  - para-chlorophenylalanine
- Learning, 15
  - memory
  - passive avoidance
  - scopolamine
- Lesions, basal forebrain, 581
  - cholinergic muscarinic binding
  - passive avoidance retention
- Lesions, kainic acid, 175
  - food intake
  - lesions, nucleus accumbens
  - morphine
  - operant behavior
  - self-administration
  - water intake
- Lesions, neurochemical, 1
  - endocrine response
  - neophobia
  - nucleus locus coeruleus
  - stress
- Lesions, nucleus accumbens, 175
  - food intake
  - lesions, kainic acid
  - morphine
  - operant behavior
  - self-administration
  - water intake
- Lesions, raphe nucleus, 97
  - monoamine oxidase inhibitors
  - mouse killing behavior
  - serotonin neurotransmission
- Lesions, striatal, 403
  - ibotenic acid
  - rotational behavior
- Lingual epithelium, 257
  - amiloride
  - 4-aminopyridine
  - transport pathways
- Locomotor activity
  - amphetamine, 517
  - cocaine effects, 157
  - heart rate, 157
  - hyperactivity, 645
  - inbred strains, 157
  - MDMA, 645
  - methysergide, 645
  - nicotine, 661
  - Pavlovian conditioning, 661
  - ultradian activity rhythms, 517
- Lorazepam, 183
  - barbital
  - brain monoamines
  - ethanol
  - motor impairment
  - selective breeding
- Lordosis
  - $\beta$ -adrenoceptors, 717
  - estradiol benzoate, 303
  - ovariectomy, 303
  - rats, females, 717
  - strychnine, 303
  - ventromedial hypothalamic nucleus
  - 303
- Luteinizing hormone levels, 489
  - alcohol, chronic administration
  - hypogonadism
  - prolactin levels
  - testosterone levels

- Malaise, 79
  - feeding/hoarding inhibition
  - phenylpropanolamine
- Marijuana, 649
  - clonidine
  - human studies, males
  - physiologic effects
  - subjective effects
- Marijuana smoke, 553
  - dosing procedure
  - human studies
- MDMA
  - brain serotonin neurons, 269
  - hyperactivity, 645
  - locomotor activity, 645
  - methysergide, 645
  - neurotoxicity, 269
- Memory, 15
  - learning
  - passive avoidance
  - scopolamine
- Memory consolidation, 321
  - ethanol
  - GABAergic mechanisms
  - passive avoidance
- Memory enhancement, 635
  - drug dose
  - training-testing interval
- 3-Mercaptopropionic acid, 525
  - caudate-putamen
  - dyskinesia
  - unilateral administration
- Methamphetamine analog, 125
  - behavioral inhibition
  - drug interaction
  - ketanserin
  - para-chlorophenylalanine
- Methamphetamine metabolism, 733
  - alcohol intake
  - human studies
  - urinary excretion
- Method
  - electroencephalography, 785
  - gas chromatography, 733
  - high performance liquid chromatography, 183
  - marijuana smoke dosing, 553
  - polysomnography, 807
  - somnography, 811
- Methsuximide, 641
  - pigeons
  - schedule-controlled responding
- 1-(3,4-Methylenedioxyphenyl)-2-aminopropane analogs, 443
  - stimulus properties
- Methysergide, 645
  - hyperactivity
  - locomotor activity
- MDMA
- Monkey
  - adenosine analogs, 429
  - 4-bromo-2,5-dimethoxyamphetamine, 281
  - caffeine, 429
  - CGS 8216, 741
  - dose-dependent effects, 741
  - drug comparisons, 741
  - drug interaction, 429
  - operant behavior, 281
  - schedule-controlled behavior, 741
  - variability of effects, 281
- adjunctive drinking
  - drug self-administration
  - scheduled-induced polydipsia
- Monkey, vervet, 115
  - brain amine metabolism
  - breakfast
  - social behavior
- Monoamine/metabolite content, 169
  - acute administration
  - ethanol tolerance
  - forebrain regions
  - selective breeding
- Monoamine oxidase inhibitors, 97
  - lesions, raphe nucleus
  - mouse killing behavior
  - serotonin neurotransmission
- Morphine
  - diabetes, 495
  - discriminative effects, 201
  - drug discrimination, 397
  - drug interactions, 387, 397
  - energy balance, 495
  - feeding behavior regulation, 387
  - food deprivation, 387
  - food intake, 175
  - lesions, kainic acid, 175
  - lesions, nucleus accumbens, 175
  - nalmefene, 495
  - naloxone, 387
  - operant behavior, 175
  - opioids, 387, 495
  - pentazocine, 397
  - pigeons, 397
  - reduced body weight, 201
  - restricted feeding, 201
  - route of administration, 387
  - salt intake, 617
  - salt preference, 617
  - self-administration, 175
  - tripelennamine, 397
  - water intake, 175
- Morris water task, 325
  - cholinergically-based learning
  - strain differences
- Motility, 249
  - habituation
  - stereotypy
  - stimulant effects
- Motor coordination, 609
  - droperidol
  - drug interaction
  - mu receptor agonists
- Motor impairment, 183
  - barbital
  - brain monoamines
  - ethanol
  - lorazepam
  - selective breeding
- Mouse killing behavior, 97
  - lesions, raphe nucleus
  - monoamine oxidase inhibitors
  - serotonin neurotransmission
- Multiple effects, 823
  - bupirone
  - central dopaminergic system
  - complex effects
- Mu receptor agonists, 609
  - droperidol
  - drug interaction
  - motor coordination
- Muscimol, 457
  - amphetamine
- GABAergic mechanisms
  - picrotoxin
  - rotational behavior
- Muscle rigidity, 573
  - alfentanil
  - brainstem site localization
  - drug interaction
- Nalmefene, 495
  - diabetes
  - energy balance
  - morphine
  - opioids
- Naloxone
  - brain self-stimulation, 209
  - diprenorphine, 209
  - drinking, 39
  - drinking modification, 331
  - drug interaction, 387
  - ethanol, 39
  - feeding behavior regulation, 387
  - fixed-ratio schedule, 209
  - food deprivation, 387
  - gonadectomy, 705
  - immobilization stress, 613
  - morphine, 387
  - noradrenaline release, 613
  - opiate peptide levels, 613
  - opioid mediation, 705
  - opioids, 387
  - route of administration, 387
  - sex differences, 705
  - swim analgesia, 705
- Neophobia, 1
  - endocrine response
  - lesion, neurochemical
  - nucleus locus coeruleus
  - stress
- Neurochemical development, 213
  - cannabinoids
  - perinatal exposure
  - tyrosine hydroxylase activity
- Neuroleptics, 205
  - anticholinergics
  - consummatory acts
  - drug interaction
  - operant behaviors
- Neurotoxicity, 269
  - brain serotonin neurons
  - MDMA
- Nicotine
  - arecoline, 587
  - behavioral interactions, 63
  - brown adipose tissue, 33
  - caffeine, 63
  - cross-tolerance, 365
  - decerebration, 725
  - discriminative stimuli, 587
  - drug interaction, 63
  - ethanol, 365
  - ethylketazocine, 725
  - fixed interval schedule, 63
  - GDP-binding, 33
  - hyperalgesia, 725
  - locomotor activity, 661
  - non-cholinergic mechanism, 587
  - Pavlovian conditioning, 661
  - thermogenesis, 33
  - tolerance, 365
- Nicotine delivery, 23
  - carbon monoxide levels



- cigarette smoking
- EEG
- heart rate
- human studies
- photic driving
- visual evoked potentials
- Nicotine gum, 747
  - chew rate
  - human studies, males
  - plasma nicotine
  - subjective effects
- Nicotinic receptors, 375
  - desensitization
  - seizures, nicotine induced
- Nifedipine, 381
  - calcium channels
  - dyskinesia
  - iminodipropionitrile
- Nigro-striatal dopamine system, 59
  - animal models
  - prolactin
  - yawning
- Nocturnal depletion, 541
  - hypothalamic dynorphin
  - rats, anorexic, tumor bearing
- Non-benzodiazepine anxiolytics, 797
  - clinical pharmacology
- Non-cholinergic mechanism, 587
  - arecoline
  - discriminative stimuli
  - nicotine
- Noradrenaline release, 613
  - immobilization stress
  - naloxone
  - opiate peptide levels
- Norepinephrine system, 83
  - analgesia
  - cold water swims
  - hypothermia
  - jump thresholds
  - thermoregulation
  - yohimbine
- Nucleus locus coeruleus, 1
  - endocrine response
  - lesion, neurochemical
  - neophobia
  - stress
- Olfactory bulbectomy, 681
  - amitryptiline, chronic
  - animal model of depression
  - <sup>3</sup>H-imipramine binding
  - open field
  - swimming test
- $\omega_1$  recognition sites, 781
  - GABA<sub>A</sub> receptor supramolecular complex
  - zolpidem
- Omega receptor subtypes, 763
  - benzodiazepine receptors
  - imidazopyridines
- Open field, 681
  - amitryptiline, chronic
  - animal model of depression
  - <sup>3</sup>H-imipramine binding
  - olfactory bulbectomy
  - swimming test
- Operant behavior
  - anticholinergics, 205
  - 4-bromo-2,5-dimethoxyamphetamine, 281
  - consummatory acts, 205
  - drug interaction, 205
  - ethanol tolerance, 105
  - food intake, 175
  - lesions, kainic acid, 175
  - lesions, nucleus accumbens, 175
  - monkeys, 281
  - morphine, 175
  - neuroleptics, 205
  - self-administration, 175
  - variability of effects, 281
  - water intake, 175
- Operant criteria, 67
  - THC discrimination
  - sensitivity
- Opiate peptide levels, 613
  - immobilization stress
  - naloxone
  - noradrenaline release
- Opioid mediation, 705
  - gonadectomy
  - naloxone
  - sex differences
  - swim analgesia
- Opioid-mediated behaviors, 9
  - analgesia, milk-induced
  - stress reduction
- Opioid peptide brain levels, 163
  - analgesia
  - central nervous system
  - cold swim stress
- Opioids
  - diabetes, 495
  - drug interaction, 387
  - energy balance, 495
  - feeding behavior regulation, 387
  - food deprivation, 387
  - morphine, 387, 495
  - nalmefene, 495
  - naloxone, 387
  - route of administration, 387
- Ovariectomy, 303
  - estradiol benzoate
  - lordosis
  - strychnine
  - ventromedial hypothalamic nucleus
- Oxidative enzymes, 53
  - brown adipose tissue
  - chronic alcohol intake
  - cold acclimation
- Oxytocin, 699
  - corticosterone
  - exogenous administration
  - prolactin
  - psychological stress
- Panic disorder, 815
  - buspirone
  - imipramine
  - placebo
- Pain responsiveness, 595
  - circadian fluctuations
  - Met-enkephalin-like immunoreactivity
- Para-chlorophenylalanine, 125
  - behavioral inhibition
  - drug interaction
  - ketanserin
  - methamphetamine analog
- Passive avoidance
  - amnesia, 625
  - diazepam, 625
  - electroconvulsive shock, 625
  - ethanol, 321
  - GABAergic mechanisms, 321
  - learning, 15
  - memory, 15
  - memory consolidation, 321
  - piracetam, 625
  - scopolamine, 15, 625
- Passive avoidance retention, 581
  - cholinergic muscarinic binding
  - lesions, basal forebrain
- Pavlovian conditioning, 661
  - locomotor activity
  - nicotine
- Pentazocine, 397
  - drug discrimination
  - drug interactions
  - morphine
  - pigeons
  - tripeleennamine
- Peptide
  - angiotensin II, 479
  - bombesin, 357
  - oxytocin, 699
- Perinatal exposure, 213
  - cannabinoids
  - neurochemical development
  - tyrosine hydroxylase activity
- Phenylethylamine, 287
  - stereotypy
  - taste aversion
- N<sup>6</sup>-L-Phenylisopropyladenosine, 533
  - adenosine receptors
  - anticonvulsant activity
  - carbamazepine
  - central nervous system
  - rabbits
- Phenylpropanolamine, 79
  - feeding/handling inhibition
  - malaise
- Photic driving, 23
  - carbon monoxide levels
  - cigarette smoking
  - EEG
  - heart rate
  - human studies
  - nicotine delivery
  - visual evoked potentials
- Physical dependence, 753
  - benzodiazepines
  - withdrawal
- Physiologic effects, 649
  - clonidine
  - human studies, males
  - marijuana
  - subjective effects
- Picrotoxin, 457
  - amphetamine
  - GABAergic mechanisms
  - muscimol
  - rotational behavior
- Pigeons
  - drug discrimination, 397
  - drug interactions, 397
  - methsuximide, 641
  - morphine, 397
  - pentazocine, 397
  - schedule-controlled responding, 641
  - tripeleennamine, 397
- Piracetam, 625
  - amnesia
  - diazepam

- electroconvulsive shock
- passive avoidance
- scopolamine
- Pituitary cyclic AMP, 151
  - plasma corticosterone
  - prolactin
  - psychological stress
- Placebo, 815
  - bupirone
  - imipramine
  - panic disorder
- Plasma corticosterone, 151
  - pituitary cyclic AMP
  - prolactin
  - psychological stress
- Plasma nicotine, 747
  - chew rate
  - human studies, males
  - nicotine gum
  - subjective effects
- Polysomnography, 807
  - sleep apnea syndrome
  - zolpidem
- Preclinical studies, 775
  - binding
  - pyrazolopyridine non-benzodiazepine
    - anxiolytics
- Pressure reversal, 133
  - ethanol
  - hyperbaric environment
  - spontaneous behavior
- Prolactin
  - animal models, 59
  - corticosterone, 699
  - exogenous administration, 699
  - nigro-striatal dopamine system, 59
  - oxytocin, 699
  - pituitary cyclic AMP, 151
  - plasma corticosterone, 151
  - psychological stress, 151, 699
  - yawning, 59
- Prolactin levels, 489
  - alcohol, chronic administration
  - hypogonadism
  - luteinizing hormone levels
  - testosterone levels
- Prostaglandin levels, 335
  - catalepsy
  - haloperidol
  - radiation
- Psychological stress
  - corticosterone, 699
  - exogenous administration, 699
  - oxytocin, 699
  - pituitary cyclic AMP, 151
  - plasma corticosterone, 151
  - prolactin, 151, 699
- Punishment suppression, 771
  - anxiety
  - anxiolytic drug effects
- Pyrazolopyridine non-benzodiazepine
  - anxiolytics, 775
    - binding
    - preclinical studies
- Pyridoxine, 565
  - behavior, fenfluramine-induced
  - fenfluramine
  - serotonin
  - tryptophan
- Rabbit, 533
  - adenosine receptors
  - anticonvulsant activity
  - carbamazepine
  - central nervous system
  - N<sup>6</sup>-L-phenylisopropyladenosine
  - Rabbit/rat comparisons, 785
    - benzodiazepine receptors
    - brain electrical activity
  - Radiation, 335
    - catalepsy
    - haloperidol
    - prostaglandin levels
  - Rat, anorexic, tumor bearing, 541
    - hypothalamic dynorphin
    - nocturnal depletion
  - Rats, female, 717
    - $\beta$ -adrenoceptors
    - lordosis
  - Real-feeding/sham-feeding comparisons, 231
    - atropine methyl nitrate
    - sucrose
  - Receptor effects, 223
    - catalepsy
    - D-1/D-2 receptor blockade
    - drug interaction
  - Receptor-mediated effects, 711
    - bupirone
    - gepirone
    - 5-hydroxytryptamine<sub>1A</sub>
    - ipsapirone
  - Reduced body weight, 201
    - discriminative effects
    - morphine
    - restricted feeding
  - Reinforcing properties, 419
    - caffeine
    - human studies
  - REM sleep deprivation, 217
    - central responses
    - cholinergic drugs
  - Renin-angiotensin system, 479
    - alcohol drinking
    - angiotensin II
    - satiety
  - Response patterning, 143
    - acquisition
    - scopolamine
    - selection delays
  - Restricted feeding, 201
    - discriminative effects
    - morphine
    - reduced body weight
  - Ro15-1788 effects, 315
    - behavioral tests
    - chlordiazepoxide actions
    - drug interaction
    - ethanol actions
  - Rotation, 89
    - dopamine receptor agonist
    - intranigral injections
  - Rotational behavior
    - amphetamine, 457
    - GABAergic mechanisms, 457
    - ibotenic acid, 403
    - lesions, striatal, 403
    - muscimol, 457
    - picrotoxin, 457
  - Route of administration
    - antinociception, 351
    - delta antagonists, 351
    - drug interaction, 387
  - feeding behavior regulation, 387
  - food deprivation, 387
  - ICI 154129, 351
  - ICI 174864, 351
  - morphine, 387
  - naloxone, 387
  - opioids, 387
- Saccharin preference, 687
  - drinking
  - eating
  - d-fenfluramine
- Satiety, 479
  - alcohol drinking
  - angiotensin II
  - renin-angiotensin system
- Salt intake, 617
  - morphine
  - salt preference
- Salt preference, 617
  - morphine
  - salt intake
- Schedule-controlled behavior
  - analgesia, 393
  - buprenorphine, 393
  - CGS 8216, 741
  - dose-dependent effects, 741
  - drug comparisons, 741
  - monkey, 741
  - tolerance, 393
- Schedule-controlled responding, 641
  - methsuximide
  - pigeons
- Schedule-induced polydipsia
  - adjunctive drinking, 295
  - apomorphine, 483
  - drug self-administration, 295
  - monkeys, rhesus, 295
- Scopolamine
  - acquisition, 143
  - amnesia, 625
  - diazepam, 625
  - electroconvulsive shock, 625
  - learning, 15
  - memory, 15
  - passive avoidance, 15, 625
  - piracetam, 625
  - response patterning, 143
  - selection delays, 143
- Seizures, 3-mercaptopropionic acid-induced, 501
  - genetic analysis
  - strain differences
- Seizures, nicotine induced, 375
  - desensitization
  - nicotinic receptors
- Selection delays, 143
  - acquisition
  - response patterning
  - scopolamine
- Selective breeding
  - acute administration, 169
  - barbital, 183
  - brain monoamines, 183
  - ethanol, 183
  - ethanol tolerance, 169
  - forebrain regions, 169
  - lorazepam, 183
  - monoamine/metabolite content, 169
  - motor impairment, 183
- Self-administration, 175

- food intake
- lesions, kainic acid
- lesions, nucleus accumbens
- morphine
- operant behavior
- water intake
- Self-rated ethanol effects, 509
  - blood ethanol levels
  - cognitive-perceptual tasks
  - ethanol
  - human studies, females
- Self-stimulation, 755
  - chronic administration
  - cocaine
  - train-duration thresholds
- Sensitivity, 67
  - THC discrimination
  - operant criteria
- Serotonin, 565
  - behavior, fenfluramine-induced
  - fenfluramine
  - pyridoxine
  - tryptophan
- Serotonin neurotransmission, 97
  - lesions, raphe nucleus
  - monoamine oxidase inhibitors
  - mouse killing behavior
- Sex differences
  - apomorphine, 529
  - behavioral differences, 529
  - gonadectomy, 705
  - haloperidol, 529
  - naloxone, 705
  - opioid mediation, 705
  - swim analgesia, 705
- Short-term exposure, 791
  - benzodiazepine receptor agonists
  - electroencephalographic changes
- Sleep apnea syndrome, 807
  - polysomnography
  - zolpidem
- Sleep organization, 827
  - Cyclic Alternating Pattern Rate
  - homeostasis
  - white noise
  - zolpidem
- Sleep pharmacology, 799
  - benzodiazepine receptor ligands
- Social behavior, 115
  - brain amine metabolism
  - breakfast
  - monkeys, vervet
- Social behavioral deficit, 467
  - animal model
  - drug behavioral reversal
- Sodium nitrate crystals, 461
  - arthritis, ankle joint
  - drug interactions
- Soman, 309
  - behavioral toxicity
  - cholinesterase inhibition
  - clonidine
- Spontaneous behavior, 133
  - ethanol
  - hyperbaric environment
  - pressure reversal
- Stereotypy
  - habituation, 249
  - motility, 249
  - phenylethylamine, 287
  - stimulant effects, 249
  - taste aversion, 287
- Stimulant effects, 249
  - habituation
  - motility
  - stereotypy
- Stimulus antagonism, 197
  - stimulus generalization
  - TFMPP stimulus properties
- Stimulus generalization, 197
  - stimulus antagonism
  - TFMPP stimulus properties
- Stimulus properties
  - 8-OH-DPAT, 193
  - drug discrimination, 193
  - ipsapirone, 193
  - 1-(3,4-methylenedioxyphenyl)-2-amino-  
propane analogs, 443
  - yohimbine, 193
- Strain differences
  - benzodiazepine receptor binding, 471
  - cholinergically-based learning, 325
  - differential modulation, 471
  - ethanol, 471
  - genetic analysis, 501
  - Morris water task, 325
  - seizures, 3-mercaptopropionic acid-  
induced, 501
  - stress, 471
- Stress
  - benzodiazepine receptor binding, 471
  - differential modulation, 471
  - endocrine response, 1
  - ethanol, 471
  - lesion, neurochemical, 1
  - neophobia, 1
  - nucleus locus coeruleus, 1
  - strain differences, 471
- Stress-induced analgesia, 451
  - adrenalectomy
  - endogenous opioids
  - $\beta$ -endorphin
- Stress reduction, 9
  - analgesia, milk-induced
  - opioid-mediated behaviors
- Stress ulceration, 129
  - calcium antagonist
  - gastrointestinal motility
- Strychnine
  - amino acids, 73
  - convulsant action, 73
  - estradiol benzoate, 303
  - hyperalgesic action, 73
  - intrathecal glycine, 73
  - lordosis, 303
  - ovariectomy, 303
  - ventromedial hypothalamic nucleus,  
303
- Subchronic administration, 239
  - amphetamine
  - apomorphine
  - behavioral hypersensitivity
  - cocaine
- Subjective effects
  - chew rate, 747
  - clonidine, 649
  - human studies, males, 649, 747
  - marijuana, 649
  - nicotine gum, 747
  - physiologic effects, 649
  - plasma nicotine, 747
- Sucrose, 231
  - atropine methyl nitrate
  - real-feeding/sham-feeding comparisons
- Swim analgesia, 705
  - gonadectomy
  - naloxone
  - opioid mediation
  - sex differences
- Swimming test, 681
  - amitriptyline, chronic
  - animal model of depression
  - $^3\text{H}$ -imipramine binding
  - olfactory bulbectomy
  - open field
- Sympathetic firing rate, 675
  - appetite suppressing drugs
  - brown adipose tissue
  - fenfluramine
- Tail-flick tests, 83
  - analgesia
  - cold water swims
  - hypothermia
  - jump thresholds
  - norepinephrine system
  - thermoregulation
  - yohimbine
- Taste aversion, 287
  - phenylethylamine
  - stereotypy
- Testosterone levels, 489
  - alcohol, chronic administration
  - hypogonadism
  - luteinizing hormone levels
  - prolactin levels
- 4,5,6,7-Tetrahydroisoxazolo (5-4-c)  
pyridin-3-ol, 189
  - baclofen
  - chronic administration
  - desipramine
  - drug interaction
  - functional response
- TFMPP stimulus properties, 197
  - stimulus antagonism
  - stimulus generalization
- THC discrimination, 67
  - operant criteria
  - sensitivity
- Therapeutic agents, 433
  - adenosine antagonists
  - caffeine
  - xanthines
- Thermogenesis, 33
  - brown adipose tissue
  - GDP-binding
  - nicotine
- Thermoregulation
  - analgesia, 83
  - cold water swims, 83
  - ethanol, 693
  - hyperthermia, 693
  - hypothermia, 83, 693
  - jump thresholds, 83
  - norepinephrine system, 83
  - tail-flick tests, 83
  - yohimbine, 83
- Thermoregulatory set point, 243
  - behavioral thermoregulation
  - ethanol
  - goldfish
  - tolerance
- Tolerance
  - analgesia, 393
  - behavioral effects, 411

- behavioral thermoregulation, 243
- buprenorphine, 393
- caffeine, 411
- cross-tolerance, 365
- ethanol, 243, 365
- goldfish, 243
- nicotine, 365
- schedule-controlled behavior, 393
- thermoregulatory set point, 243
- Train-duration thresholds, 755
  - chronic administration
  - cocaine
  - self-stimulation
- Training-testing interval, 635
  - drug dose
  - memory enhancement
- Transport pathways, 257
  - amiloride
  - 4-aminopyridine
  - lingual epithelium
- Tripelennamine, 397
  - drug discrimination
  - drug interactions
  - morphine
  - pentazocine
  - pigeons
- Tryptophan
  - behavior, fenfluramine, 565
  - brain serotonin, 559
  - dietary pyridoxine, 559
  - fenfluramine, 565
  - histadine, 559
  - histamine metabolism, 559
  - pyridoxine, 565
  - serotonin, 565
- Tyrosine hydroxylase activity, 213
  - cannabinoids
  - neurochemical development
  - perinatal exposure
- Ultradian activity rhythms, 517
  - amphetamine
  - locomotor activity
- Unilateral administration, 525
  - caudate-putamen
- dyskinesia
  - 3-mercaptopyruvic acid
- Urinary excretion, 733
  - alcohol intake
  - human studies
  - methamphetamine metabolism
- Variability of effects, 281
  - 4-bromo-2,5-dimethoxyamphetamine
  - monkeys
  - operant behavior
- Ventromedial hypothalamic nucleus, 303
  - estradiol benzoate
  - lordosis
  - ovariectomy
  - strychnine
- Voluntary consumption, 601
  - ethanol
  - genetic correlation
  - withdrawal
- Visual evoked potentials, 23
  - carbon monoxide levels
  - cigarette smoking
  - EEG
  - heart rate
  - human studies
  - nicotine delivery
  - photic driving
- Water intake, 175
  - food intake
  - lesions, kainic acid
  - lesions, nucleus accumbens
  - morphine
  - operant behavior
  - self-administration
- Wheel-running activity, 667
  - body weight
  - circadian rhythm
  - dose-dependent effects
  - drinking
  - eating
  - ethanol
- Withdrawal
  - benzodiazepines, 753
  - ethanol, 601
  - genetic correlation, 601
  - physical dependence, 753
  - voluntary consumption, 601
- White noise, 827
  - Cyclic Alternating Pattern Rate
  - homeostasis
  - sleep organization
  - zolpidem
- Xanthines, 433
  - adenosine antagonists
  - caffeine
  - therapeutic agents
- Yawning, 59
  - animal models
  - nigro-striatal dopamine system
  - prolactin
- Yohimbine
  - analgesia, 83
  - cold water swims, 83
  - 8-OH-DPAT, 193
  - drug discrimination, 193
  - hypothermia, 83
  - ipsapirone, 193
  - jump thresholds, 83
  - norepinephrine system, 83
  - stimulus properties, 193
  - tail flick tests, 83
  - thermoregulation, 83
- Zolpidem
  - Cyclic Alternating Pattern Rate, 827
  - GABA<sub>A</sub> receptor supramolecular complex, 781
  - homeostasis, 827
  - $\omega_1$  recognition sites, 781
  - sleep apnea syndrome, 807
  - sleep organization, 827
  - polysomnography, 807
  - white noise, 827
- Zopiclone, 831
  - cyclopyrrolone hypnotic, 831

## AUTHOR INDEX

- |   |  |   |
|---|--|---|
| <ul style="list-style-type: none"> <li>Abelson, M. L., 617</li> <li>Agrasal, C., 489</li> <li>Akkok, F., 331</li> <li>Aldrich-Castanik, L., 315</li> <li>Algeri, S., 823</li> <li>Allen, J. D., 483</li> <li>Altman, H. J., 581</li> <li>Alvarez, W. F., 45</li> <li>Anelli, S., 827</li> <li>Arase, K., 675</li> <li>Arbilla, S., 763</li> <li>Arcelloni, T., 827</li> <li>Aronstam, R. S., 309</li> <li>Asin, K. E., 89</li> <li>Avril, I., 625</li> <li>Baldessarini, R. J., 517</li> <li>Banas, C., 73</li> </ul> | <ul style="list-style-type: none"> <li>Bansinath, M., 609</li> <li>Barber, N. I., 517</li> <li>Bare, T. M., 775</li> <li>Barnhill, J. G., 471</li> <li>Baron, S. P., 143</li> <li>Barr, S. I., 667</li> <li>Bartholini, G., 833</li> <li>Battaglia, G., 269</li> <li>Bean, A. J., 357</li> <li>Bedichek, R. C., 243</li> <li>Benedetti, M., 533</li> <li>Beninger, R. J., 249</li> <li>Benowitz, N. L., 747</li> <li>Berge, O.-G., 133</li> <li>Berman, R. F., 581</li> <li>Berthold, C. W., III, 393</li> <li>Bertino, M., 617</li> <li>Beyer, C., 73, 303</li> </ul> | <ul style="list-style-type: none"> <li>Bignami, G., 771</li> <li>Billington, C. J., 495</li> <li>Bird, D. C., 105</li> <li>Blasco, T. A., 573</li> <li>Blass, E. M., 9</li> <li>Block, H., 223</li> <li>Blois, R., 799</li> <li>Boal, A. S., 115</li> <li>Bodnar, R. J., 83, 705</li> <li>Bodor, A. S., 601</li> <li>Borrell, J., 39</li> <li>Borsini, F., 189, 275</li> <li>Bowden, C. R., 357</li> <li>Bowers, A., 93</li> <li>Bray, G. A., 33, 675</li> <li>Brown, D. M., 495</li> <li>Brun, J. P., 831</li> <li>Bryant, H. U., 541</li> <li>Buccafusco, J. J., 15, 309</li> <li>Bunnell, B. N., 151</li> <li>Burch, J. B., 365</li> <li>Burkhardt, C. A., 617</li> <li>Cadet, J. L., 125, 381</li> <li>Carlini, E. A., 217</li> <li>Carr, L. A., 213</li> <li>Castellano, C., 321</li> <li>Chait, L. D., 553</li> <li>Chan, A. W. K., 315</li> <li>Chan, A., 635</li> <li>Chermat, R., 625</li> <li>Ciesielski, L., 97</li> <li>Cirignotta, F., 807</li> <li>Clark, C. R., 125</li> <li>Cline, E. J., 573</li> <li>Coderre, T. J., 461</li> </ul> |
|---|--|---|

- Collins, A. C., 157, 365, 375  
 Commissaris, R. L., 631  
 Cone, E. J., 649  
 Coppinger, R., 115  
 Corwin, R. L., 553  
 Crabbe, J. C., 243, 601  
 Crawshaw, L. I., 243  
 Crosland, R. D., 581  
 Czirr, S. A., 331
- Dalton, T. K., 335  
 D'Aranno, V., 275  
 Deakin, J. F. W., 819  
 de Fiebre, C. M., 365  
 Delaney, D., 641  
 Del Rio, J., 387  
 De Luigi, A., 823  
 De Maio, D., 821  
 De Medici, D., 785  
 De Robertis, E., 681  
 De Simoni, M. G., 823  
 De Souza, E. B., 269  
 Di Nicolantonio, R., 547  
 Dworkin, S. I., 175  
 Dykstra, L. A., 397
- Elrod, K., 15  
 Ervin, F. R., 115  
 Esquifino, A. I., 489  
 Evangelista, S., 275
- Fahn, S., 125  
 Farolfi, A., 807, 827  
 Feroso, J., 489  
 Fernandez-Tome, M. P., 387  
 Finn, I. B., 411  
 Fioriti, G., 827  
 Fisher, H., 559, 565  
 Fisher, J. S., 609  
 Fitzgerald, E., 9  
 Fletcher, P. J., 687  
 Flood, J. F., 635  
 Francès, H., 467  
 Frank, R. A., 755  
 Freed, W. J., 381
- Garcia-Cabrera, I., 133  
 Gaillard, J.-M., 799  
 Gatto, G. J., 169  
 Gerardi, R., 807  
 Gesellchen, P. D., 351  
 Giles, R. E., 775  
 Giuliani, S., 189  
 Glennon, R. A., 197, 443  
 Gobballe, S., 97  
 Goeders, N. E., 175  
 Gold, L. H., 645  
 Goldberg, M. E., 775  
 Goldberg, S. R., 429  
 Golding, J. F., 23  
 Gomora, P., 73  
 Gonzalez, Y., 387  
 Gordon, C. J., 693  
 Gorzalka, B. B., 717  
 Gosnell, B. A., 495  
 Grace, M., 495  
 Graefe, J. F., 93  
 Graham, J. H., 309  
 Grant, K. A., 295  
 Gray, J. A., 767  
 Greenblatt, D. J., 471  
 Greenwald, N. E., 509
- Griffiths, R. R., 419  
 Grupp, L. A., 479  
 Guaza, C., 39  
 Gudelsky, G. A., 711  
 Guerin, G. F., 175
- Hakan, R. L., 661  
 Hellevuo, K., 183  
 Henningfield, J. E., 747  
 Holloway, J. A., 105  
 Holloway, F. A., 105  
 Holtzman, S. G., 411  
 Hunt, W. A., 335  
 Huttunen, P., 53
- Ida, Y., 613  
 Imeri, L., 823  
 Isel, F., 97
- Jarvis, M. F., 433  
 Jenden, D. J., 581  
 Johanson, C. E., 295, 553  
 Joseph, J. A., 335
- Kafetzopoulos, E., 403, 457  
 Kandasamy, S. B., 335  
 Kant, G. J., 151  
 Karkanas, C. D., 357  
 Katz, J. L., 429  
 Kempf, E., 1  
 Kepler, K. L., 83, 705  
 Kiianmaa, K., 183  
 Killian, M., 479  
 Klemm, W. R., 223  
 Koenig, J. I., 711  
 Komisaruk, B. R., 73, 103  
 Konitsiotis, S., 403  
 Koob, G. F., 573, 645  
 Kortelainen, M.-L., 53  
 Kosobud, A., 601  
 Krahn, D. D., 495  
 Ksir, C. J., 661  
 Kumar, M. S. A., 451  
 Kumar, S., 725  
 Kuramaji, A., 595  
 Kutscher, C. L., 287
- Lader, M., 797  
 Lajtha, A., 525  
 Langan, M. C., 315  
 Lange, W. R., 649  
 Langer, S. Z., 763  
 Laping, N. J., 59  
 Leander, J. D., 351  
 Lee, N. S., 559, 565  
 Lenègre, A., 625  
 Leong, F. W., 315  
 Levine, A. S., 495  
 Levy, A., 79  
 Lex, B. W., 509  
 Li, T.-K., 169  
 Lloyd, K. G., 781  
 Ljungberg, T., 205  
 Longo, V. G., 761, 785  
 Lugaresi, E., 807  
 Lukas, S. E., 509  
 Lumeng, L., 169  
 Lupien, J. R., 33
- McBride, W. J., 169  
 McCloskey, T. C., 631  
 McKearney, J. W., 281
- McKenney, J. D., 197  
 Magar, K., 93  
 Malick, J. B., 753, 775  
 Malven, P. V., 541  
 Mancinelli, A., 275  
 Mandel, P., 97  
 Manha, N. A., 331  
 Marconi, M., 823  
 Marglin, S. H., 617  
 Marks, M. J., 365  
 Marley, R. J., 501  
 Martin, B. J., 501  
 Martin, I., 489  
 Martin, W. R., 725  
 Martz, S., 755  
 Massotti, M., 785, 791  
 Mateos, A., 489  
 May, J. E., 45  
 Mazurski, E. J., 249  
 Means, L. W., 67  
 Meiners, B. A., 775  
 Meli, A., 189, 275  
 Meltzer, H. Y., 711  
 Meltzer, L. T., 587  
 Mendelsohn, L. G., 351  
 Mendelson, S. D., 717  
 Meyerhoff, J. L., 151  
 Michael, R. P., 209  
 Michaelis, R. C., 105  
 Miczek, K. A., 451  
 Miller, L. G., 471  
 Miner, L. L., 375, 501  
 Moerschbaecher, J. M., 393  
 Mokler, D. J., 67  
 Molina, V., 97  
 Mondini, S., 807  
 Montana, W. E., 89  
 Morley, J. E., 495  
 Mormede, P., 1  
 Morselli, P. L., 803  
 Muhs, G., 559  
 Muir, J. L., 699  
 Murphy, J. M., 169  
 Musch, B., 803
- Nava, S., 823  
 Nemeth-Coslett, R., 747  
 Neuman, R., 617  
 Nielsen, S. T., 129  
 Nissenbaum, J. W., 231  
 Noda, K., 451
- O'Connor, C. S., 243  
 Ohi, K., 595  
 Oliveto, A. H., 397  
 O'Neal, M. F., 67
- Parrino, L., 827  
 Patel, J. B., 753, 775  
 Patrick, G., 443  
 Pavone, F., 321  
 Peele, D. B., 143  
 Pellettiere, V., 641  
 Penetrante, M. L., 315  
 Perego, C., 823  
 Perlanski, E., 479  
 Pfeffer, A. O., 343  
 Pfister, H. P., 699  
 Pierson, M. E., 197  
 Poling, A., 641  
 Pommering, T., 755  
 Popoli, P., 533
- Porsolt, R. D., 625  
 Porter, J. H., 67  
 Prada, J. A., 429  
 Priore, P., 803  
 Puig, M. M., 609
- Raj, A. B., 815  
 Ramirez, V. D., 59  
 Reid, L. D., 331, 617  
 Reynolds, R. D., 559  
 Richard, C. W., III, 163  
 Riffée, W. H., 239  
 Rinarelli, C. A., 753  
 Robb, R., 257  
 Robinson, N., 747  
 Romero, M.-T., 705  
 Rosecrans, J. A., 67, 587  
 Roudebush, R. L., 169  
 Ruth, J. A., 157
- Sacchetti, G., 823  
 Sakaguchi, T., 675  
 Salama, A. I., 775  
 Samson, H. H., 343  
 Sandi, C., 39  
 Sandoval, Y., 303  
 Santos, R., 217  
 Schaefer, G. J., 209  
 Schanley, D. L., 315  
 Schiffman, S. S., 257  
 Schlinger, H., 641  
 Sclafani, A., 231  
 Scotti de Carolis, A., 533  
 Serra, J., 681  
 Shader, R. I., 471  
 Shaywitz, B. A., 517  
 Sheehan, D. V., 815  
 Sheehan, K. H., 815  
 Shimamoto, K., 733  
 Shuster, L., 451  
 Simon, S. A., 257  
 Slater, J. P., 509  
 Slifer, B. L., 397  
 Sloan, J. W., 725  
 Smith, G. E., 635  
 Smith, J. E., 175  
 Smith, N. T., 573  
 Snodgrass, S. H., 483  
 Snyder, C. A., 93  
 Soto, S., 815  
 Spaggiari, M. C., 827  
 Spealman, R. D., 741  
 Stead, A. G., 693  
 Steele, T. D., 541  
 Steru, L., 625  
 Stevens, S., 335  
 Stewart, R. B., 479  
 Stockert, M., 681  
 Stone, R. K., 45  
 Sulkowski, T. S., 129  
 Sutherland, M., 115
- Takahashi, K., 595  
 Takashima, M., 595  
 Tanaka, M., 613  
 Tang, C. K., 609  
 Taylor, E., 381  
 Teicher, M. H., 517  
 Tejwani, G. P., 163  
 Terzano, M. G., 827  
 Thompson, M. L., 451  
 Toth, E., 525

Trout, J. R., 565  
Tsuda, A., 613  
Turndorf, H., 609  
  
Ukai, M., 201  
Ullman, E. A., 157  
Upchurch, M., 325  
U'Prichard, D. C., 775  
  
Valerio, A., 785, 791  
Van De Poll, N. E., 529

Van Haaren, F., 529  
Van Hest, A., 529  
Vasas, R. J., 631  
Vaswani, K. K., 163  
Velley, L., 1  
Vlaha, V., 403  
  
Wagner, G. C., 559, 565  
Wall, P. D., 461  
Walters, D. E., 213  
Wanek, E., 239

Wehner, J. M., 325, 501  
Weinger, M. B., 573  
Weisinger, R. S., 547  
Welch, P., 649  
Wellman, P. J., 79  
Wettstein, J. G., 741  
Wheatley, D., 811  
White, J. M., 63  
Wilcox, R. E., 239  
Williams, M., 433  
Winter, J. C., 193

Wood, R. W., 93  
Woodson, P. P., 419  
  
Yeh, S. Y., 269  
Yim, G. K. W., 541  
Young, S. N., 115  
Yousif, M., 443  
  
Zivkovic, B., 781  
Zucconi, M., 807